Digital healthcare company Huinno (CEO Gil Young-jun) has signed a domestic licensing agreement with Yuhan Corporation for its artificial intelligence (AI)-based smart in-hospital monitoring solution, 'MEMO Cue.'
MEMO Q is a complex medical device comprised of the MEMO Patch electrocardiogram monitor, the MEMO Band pulse oximeter, and the MEMO Band integrated in-hospital monitoring system, which monitors the vital signs of hospitalized patients at a glance. In February, it secured health insurance coverage for "ECG monitoring (remote cardiac rhythm monitoring, EX871)" from the Health Insurance Review & Assessment Service, laying the foundation for full-scale commercialization.
The collaboration between Yuhan-Yanghaeng and Huinno is already yielding results, particularly at tertiary hospitals in Korea. As part of their digital healthcare collaboration, the two companies signed a domestic licensing agreement for the Memo Patch in 2022 and have been working to expand its adoption, particularly in tertiary hospitals. In July, Severance Hospital in Sinchon surpassed 10,000 cumulative Memo Patch tests, marking the largest single-site medical institution in Korea. Building on this success, Yuhan-Yanghaeng plans to leverage its network of tertiary hospitals in Korea to support the rapid expansion of Memo Q.
A Yuhan Corporation representative stated, “Since 2020, we have been leading the change in the early arrhythmia diagnosis market, focusing on domestic tertiary hospitals, through Huinno’s Memo Patch, contributing to improving patients’ quality of life.” They added, “MemoQ is a practical solution that can improve the quality of medical services by contributing to the shortage of hospital personnel.” They continued, “We plan to quickly distribute it by leveraging our hospital network so that we can establish ourselves as a key solution leading the global digital healthcare market.”
Gil Young-jun, CEO of Huinno, said, "This agreement marks a shift from a single-product-focused approach to a solution-based collaboration. We will combine our medical AI technology with Yuhan Corporation's market dominance to create significant synergy." He added, "Through continued close collaboration, we will strengthen our competitiveness in the domestic digital healthcare market and deliver innovative value to both patients and medical professionals."
- See more related articles
You must be logged in to post a comment.